Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for de novo hepatitis B during solid cancer treatment.
Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Sugimoto R, et al. Among authors: senju t. World J Clin Cases. 2020 Dec 26;8(24):6264-6273. doi: 10.12998/wjcc.v8.i24.6264. World J Clin Cases. 2020. PMID: 33392307 Free PMC article.
Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma.
Sugimoto R, Inada H, Tanaka Y, Senju T, Aratake Y, Nakanishi A, Miki M, Lee L, Hisano T, Matsumoto Y, Mano Y, Iguchi T, Sugimachi K, Okumura Y, Taguchi K, Furukawa M. Sugimoto R, et al. Among authors: senju t. Clin J Gastroenterol. 2021 Oct;14(5):1484-1490. doi: 10.1007/s12328-021-01470-y. Epub 2021 Jun 27. Clin J Gastroenterol. 2021. PMID: 34176067 Free PMC article.
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Sugimoto R, Motomura K, Ooho A, Aratake Y, Ueda A, Senju T, Tanaka Y, Yada M, Tanaka K, Kuwano A, Morita Y, Nagasawa S, Ooe M, Mutsuki T, Yoshimoto T, Yamashita N, Nakashima M, Hioki T, Koyanagi T, Higuchi N, Nakamura T, Harada S, Tanaka M, Tada S, Satoh T, Uchimura K, Kuniyoshi M, Nakamuta M, Kohjima M; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: senju t. Intern Med. 2022;61(21):3157-3164. doi: 10.2169/internalmedicine.9237-21. Epub 2022 Nov 1. Intern Med. 2022. PMID: 36328582 Free PMC article.
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Ooho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: senju t. Medicine (Baltimore). 2022 Oct 7;101(40):e30871. doi: 10.1097/MD.0000000000030871. Medicine (Baltimore). 2022. PMID: 36221372 Free PMC article.
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y. Niizeki T, et al. Among authors: senju t. Target Oncol. 2022 Nov;17(6):643-653. doi: 10.1007/s11523-022-00921-x. Epub 2022 Oct 22. Target Oncol. 2022. PMID: 36272060 Free PMC article.
25 results